Managing Drug Interactions in the Treatment of HIV-Associated TB

These updated guidelines provide recommendations for managing drug interactions between rifamycin antibiotics and four classes of antiretrovirals and for co-treatment of tuberculosis and HIV infection in children and pregnant women.

Sponsoring Organization: CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination

Target Population: Primary care providers, HIV/tuberculosis (TB) treatment providers

Background and Objective

Co-treatment of TB and HIV infection is often complicated by adherence challenges, overlapping side effects, immune reconstitution inflammatory syndrome, and drug–drug interactions.

What's Changed

Recommendations for use of newer antiretrovirals, including CCR5-receptor antagonists and integrase inhibitors, are now provided. Other new features include the following:

Summaries of clinical experience with use of specific antiretroviral therapy (ART) regimens during TB treatment, together with pharmacokinet…

Reviewing Author

Salim S. Abdool Karim, MD, PhD

Disclosures

Consultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council

Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council

Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes